Tokyo, Oct 20, 2006 (JCN) - Shionogi & Co., Ltd. today announced that it has received manufacturing and marketing approval on October 20 for OXINORM powder 0.5% (oxycodone hydrochloride hydrate), a powder analgesic for pain associated with cancer. Shionogi plans to launch OXINORM in February 2007, after its National Health Insurance (NHI) price listing.
